Ocugen to Present at 2025 BIO International Convention with Key Milestones and Updates

Strategic Insights -

Ocugen, a biotechnology company, will present at the 2025 BIO International Convention, where the company's leadership team will engage with potential partners and pharmaceutical executives to explore opportunities for its modifier gene therapy platform targeting major blindness diseases. The company has achieved significant milestones, including FDA alignment for a Phase 2/3 pivotal confirmatory trial and Rare Pediatric Disease Designation for OCU410ST. Ocugen's leadership, including Dr. Shankar Musunuri, will participate in various panel discussions and presentations, highlighting the company's progress and future prospects.

Key Takeaways:

  • Ocugen will present at the 2025 BIO International Convention from June 16-19 at the Boston Convention & Exhibition Center.
  • The company's leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities for its novel modifier gene therapy platform.
  • Ocugen has recently executed a binding term sheet with a well-established leader in the pharmaceutical and healthcare sector in Korea for exclusive Korean rights to OCU400.
  • The company's modifier gene therapy platform has achieved several critical milestones, including FDA alignment for the Phase 2/3 pivotal confirmatory trial and Rare Pediatric Disease Designation for OCU410ST.
  • Enrollment is nearing completion for the OCU400 Phase 3 liMeliGhT clinical trial, and the program remains on track to file a Biologics License Application (BLA) mid-2026.
  • Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will participate in panel discussions and presentations, including "Optimizing Your Clinical Program Outcomes" and "Navigating the Regulatory Landscape."
  • Ocugen's clinical programs and near-term catalysts will be presented at Booth #1875 during the convention.

Statistics:

  • 2025 BIO International Convention: the event will take place from June 16-19 at the Boston Convention & Exhibition Center.
  • Number of meetings with potential partners and pharmaceutical executives: not specified.
  • Exclusive Korean rights to OCU400: acquired through a binding term sheet with a well-established leader in the pharmaceutical and healthcare sector in Korea.
  • FDA alignment for the Phase 2/3 pivotal confirmatory trial: achieved for OCU410ST.
  • Rare Pediatric Disease Designation: granted for OCU410ST.
  • Enrollment completion for the OCU400 Phase 3 liMeliGhT clinical trial: nearing completion.
  • Biologics License Application (BLA) filing: expected mid-2026.
  • Booth number for Ocugen's presentations: #1875.

Sources:

  • "Ocugen to Present at 2025 BIO International Convention," Ocugen, Inc.
  • ((Comments on this story may be sent to newsdesk@closeupmedia.com))